ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company

🗓 Founded 9184👥 383 employees💰 Last funded Feb 2012
Biotechnology Research🌐 imclone.com
Website LinkedIn
ImClone Systems is a fully integrated global biopharmaceutical company committed to advancing oncology care by developing and commercializing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers. On November 24, 2008, ImClone Systems became a wholly-owned subsidiary of Eli Lilly and Company (NYSE: LLY).
3
Total investors
3
Early stage
0
Mid stage
0
Late stage
9184
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Brazil
3
Investor activity2011–2012 · investors recorded per year
2011220121
Recent (last 2y)Earlier
Frequently asked questions
Who invested in ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company?
ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company has 3 investors on record on gritt.io, including 3 early-stage backers.
When did ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company last raise funding?
The most recent investment in ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company recorded on gritt.io was in February 2012.
When was ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company founded?
ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company was founded in 9184.
What industry is ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company in?
ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.